Get the Stockscreener App
2.14
1.90%
0.04
Tuhura Biosciences Inc stock is traded at $2.14, with a volume of 367.76K.
It is up +1.90% in the last 24 hours and up +2.39% over the past month.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
See More
Previous Close:
$2.10
Open:
$2.09
24h Volume:
367.76K
Relative Volume:
0.78
Market Cap:
$136.37M
Revenue:
-
Net Income/Loss:
$-30.92M
P/E Ratio:
-3.5495
EPS:
-0.6029
Net Cash Flow:
$-27.39M
1W Performance:
+1.42%
1M Performance:
+2.39%
6M Performance:
+30.49%
1Y Performance:
-15.42%
1-Day Range:
$2.06
$2.155
1-Week Range:
$2.005
$2.23
52-Week Range:
$0.41
$3.43
Tuhura Biosciences Inc Stock (HURA) Company Profile
Name
Tuhura Biosciences Inc
Sector
Industry
Phone
813-875-6600
Address
10500 UNIVERSITY CENTER DR., TAMPA
Compare HURA vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HURA
Tuhura Biosciences Inc
|
2.14 | 141.47M | 0 | -30.92M | -27.39M | -0.6029 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Tuhura Biosciences Inc Stock (HURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Initiated | Citizens | Mkt Outperform |
| Mar-03-25 | Initiated | H.C. Wainwright | Buy |
| Dec-19-24 | Initiated | Rodman & Renshaw | Buy |
| Nov-05-24 | Initiated | Maxim Group | Buy |
Tuhura Biosciences Inc Stock (HURA) Latest News
TuHURA Biosciences | 8-K: Current report - Moomoo
Form 8K TuHURA Biosciences Inc For: 19 August By Investing.com - Investing.com South Africa
TuHURA (HURA) Technicals: Closes 5.56% Higher at $2.28 in the Latest Session; Boundary Watch: the Supplied Trading Band Runs From $2.17 to $2.39Breakout Confirmation - dars.gov.et
TuHURA Biosciences stockholders approve share issuance, elect directors at annual meeting - Investing.com Canada
HURA: All proposals passed, including director elections and share issuance, with no stockholder questions - TradingView
HURA: All proposals, including director elections and share issuance, were approved without dissent - TradingView
Citizens reiterates TuHURA Biosciences stock rating on pipeline progress By Investing.com - Investing.com South Africa
HURA Q2 2026 Earnings: Narrower Loss Beats Estimates, Shares Jump 7.4%Low Estimate Range - vinanet.vn
TuHURA Biosciences Expect Preliminary Results From IR Study IFX-2.0 With Keytruda for Deep Seated MCC in 1H2027 >HURA - Moomoo
TuHURA Biosciences Extends Runway as Immuno-Oncology Pipeline Advances - TipRanks
TuHURA Biosciences (NASDAQ:HURA) Posts Earnings Results, Beats Estimates By $0.01 EPS - MarketBeat
TuHURA Biosciences Highlights Phase III IFx Push, AML Trial Plans at Canaccord - MarketBeat
TuHURA Biosciences, Inc.Common Stock (HURA) Stock Price, News, Quote & History - FinancialContent
TuHURA Biosciences Q2 Results: EPS beats estimate, losses narrow 33% YoY - scanx.trade
TuHURA Secures $50M Credit Facility Extending Cash Runway into 2028 - Minichart
Tuhura Biosciences Reports Second Quarter 2026 Financial Results And Provides A Corporate Update - TradingView
Form 8K TuHURA Biosciences Inc For: 14 August By Investing.com - Investing.com Nigeria
TuHURA Biosciences (HURA) deepens R&D spend and adds $50M credit facility - Stock Titan
TuHURA Reports $1.0 Million Cash and Advances TBS-2025 AML Program - Quiver Quantitative
TuHURA Bios reports Q2 2026: $1.0M cash, R&D $6.6M, $50M credit facility extends runway - TradingView
TuHURA Biosciences Reports Second Quarter 2026 Financial Results and Provides a Corporate Update - PR Newswire
TuHURA Biosciences Expands Use of Revolving Credit Facility - TipRanks
TuHURA Biosciences (HURA) Earnings Date and Reports 2026 - marketbeat.com
TuHURA at canaccord growth conference: late-stage push gains traction By Investing.com - Investing.com Nigeria
TuHURA at canaccord growth conference: late-stage push gains traction - Investing.com
Enterprise value to EBIT forward of TuHURA Biosciences, Inc. – NASDAQ:HURA - TradingView
HURA Q2'26 Earnings: revenue estimate is 0 USD - TradingView
TuHURA Biosciences (HURA) Expected to Release Quarterly Earnings on Thursday - MarketBeat
TuHURA Biosciences (HURA) Slips 1.38% as Biotech Stock Holds Above Key $2.03 SupportGap Up Stocks - vinanet.vn
HURA Q1 2026 Earnings: EPS Miss Widens as Pre-Revenue Oncology Pipeline Drives CostsNew Analyst Coverage - vinanet.vn
HURA Q1 2026 Earnings: EPS Miss With No Revenue and Stock Advance Defies ResultsSurprise Factor Analysis - Vinanet
TuHURA Biosciences (HURA) Dips 5.9% as Stock Tests Key Support Near $2.00Call Resistance - vinanet.vn
TuHURA Biosciences Inc (HURA) Cash Flow - TradingKey
TuHURA Biosciences Inc (HURA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TuHURA Biosciences Inc (HURA) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TuHURA Biosciences Inc (HURA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
HURA|TuHURA Biosciences Inc|Price:2.110|Chg%:-0.040 - TradingKey
TradingKey - TradingKey
HURA|TuHURA Biosciences Inc|Price:2.210|Chg%:+0.100 - TradingKey
TuHURA Biosciences, Inc. (NASDAQ:HURA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
HURA Stock Price, Quote & Chart - ChartMill
TuHURA Biosciences to Present at Canaccord Genuity Conference - Intellectia AI
TuHURA CEO to present at Canaccord Genuity Grow... - Pluang
TuHURA Biosciences to Present at Canaccord Genuity's 46th Annual Growth Conference - PR Newswire
TuHURA Biosciences (HURA) Proxy filing Summary - Quartr
TuHURA Biosciences (HURA) Registration filing Summary - Quartr
TuHURA Biosciences Inc. (HURA) Q1 2026 Earnings: EPS Miss and Pre-Revenue ChallengesDividend Earnings Report - dars.gov.et
TuHURA Biosciences (HURA) Slips Slightly as Stock Hovers Near Support LevelsEntry Point Alerts - dars.gov.et
Form DEF 14A TuHURA Biosciences For: 9 July By Investing.com - Investing.com Nigeria
TuHURA Biosciences (HURA) Stock Forum and Discussion - Moomoo
TuHURA Biosciences, Inc. (NASDAQ: HURA) Files 8-K Report Detailing Company Information and Compliance Updates – Minichart - Minichart
Tuhura Biosciences Inc Stock (HURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):